Krystal Biotech (KRYS) – Analysts’ Weekly Ratings Updates

Krystal Biotech (NASDAQ: KRYS) recently received a number of ratings updates from brokerages and research firms:

• 10/23/2026 – Krystal Biotech was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 10/23/2026 – Krystal Biotech was downgraded by Zacks Research from “hold” to “strong sell”.
• 10/15/2026 – Krystal Biotech had its “buy” rating reaffirmed by Citigroup.
• 10/15/2026 – Krystal Biotech had its “buy” rating reaffirmed by HC Wainwright. They now have a $361.00 price target on the stock.
• 10/9/2026 – Krystal Biotech was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
• 9/24/2026 – Krystal Biotech was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 9/24/2026 – Krystal Biotech is now covered by The Goldman Sachs Group. They set a “buy” rating and a $441.00 price target on the stock.
• 9/24/2026 – Krystal Biotech is now covered by The Goldman Sachs Group. They set a “buy” rating and a $441.00 price target on the stock.
• 9/23/2026 – Krystal Biotech was upgraded by William Blair to “strong-buy”.
• 9/21/2026 – Krystal Biotech had its price target raised by Bank of America from $392.00 to $400.00. They now have a “buy” rating on the stock.

Insider Transactions at Krystal Biotech

In related news, Director Dino Rossi sold 25,000 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the sale, the director owned 50,000 shares of the company’s stock, valued at $16,456,000. This trade represents a 33.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $359.32, for a total value of $8,983,000.00. Following the transaction, the insider directly owned 1,302,145 shares in the company, valued at approximately $467,886,741.40. The trade was a 1.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.10% of the company’s stock.

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company’s platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal’s lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.